2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological Activity
BIX-01294 is an inhibitor of G9a Histone Methyltransferase with IC50 of 1.9 μM.
In Vitro
BIX-01294 (4.1 μM) treatment of G9anull ES cells results in a further reduction in H3K9me2 levels. BIX-01294 reduces H3K9me2 at several G9a target genes[1]. BIX-01294 (5 µM) reduces levels of global H3K9 methylation in pronuclear- and 2-cell-stage embryos. Embryos transiently exposed to BIX-01294 have a reduced ability to establish pregnancy[2]. BIX-01294 (1 µg/mL) causes reduction in the BrdU incorporation of fetal PASMCs. BIX-01294 treatment decreases the PASMCs migration induced by PDGF[3].
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
UNC0321 is a potent and selective G9a inhibitor with Ki of 63 pM, UNC0321 is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date.It was found that replacing the 5-carbon chain in…
UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8 with IC50 of 7.3±1.0 uM; selective over 15 other methyltransferases.UNC0379 is a synthetic small-molecule inhibitor that…
EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.IC50 value: < 3 nM ( Ki for wt…